OBJECTIVES: Small cell carcinoma (SCC) of the pancreas is a rare malignancy with a poor prognosis. We established and characterized a primary human pancreatic SCC cell line, designated A99. METHODS: Cancer tissue was obtained from the liver metastasis of an SCC of the pancreas and xenografted into nude mice. The first-pass xenograft was then used to establish a cultured cell line called A99. Cellular morphology, immunohistochemical properties, tumorigenic potential, and genetic alterations of this new line were characterized. RESULTS: A99 cells grew consistently in culture, formed colonies in soft agar, and grew as subcutaneous xenografts when inoculated into nude mice. A99 cells were positive for pancytokeratin, synaptophysin, chromogranin A, neuron-specific enolase, CD57 (Leu7), CD56, protein gene product 9.5, thyroid transcription factor 1, Smad4, p53, and p16, but not for CD99, PDX-1, or retinoblastoma protein. Sequencing analysis revealed homozygous point mutations of KRAS and TP53. Cytogenetic analysis revealed complex chromosomal rearrangements including marker chromosomes. CONCLUSIONS: A99 is the first cell line reported to be derived from a primary SCC of the pancreas. The establishment of this cell line may serve as a useful model system for studying the cell biology of this rare cancer or for evaluating novel targeted agents in preclinical models.
OBJECTIVES:Small cell carcinoma (SCC) of the pancreas is a rare malignancy with a poor prognosis. We established and characterized a primary humanpancreatic SCC cell line, designated A99. METHODS:Cancer tissue was obtained from the liver metastasis of an SCC of the pancreas and xenografted into nude mice. The first-pass xenograft was then used to establish a cultured cell line called A99. Cellular morphology, immunohistochemical properties, tumorigenic potential, and genetic alterations of this new line were characterized. RESULTS: A99 cells grew consistently in culture, formed colonies in soft agar, and grew as subcutaneous xenografts when inoculated into nude mice. A99 cells were positive for pancytokeratin, synaptophysin, chromogranin A, neuron-specific enolase, CD57 (Leu7), CD56, protein gene product 9.5, thyroid transcription factor 1, Smad4, p53, and p16, but not for CD99, PDX-1, or retinoblastoma protein. Sequencing analysis revealed homozygous point mutations of KRAS and TP53. Cytogenetic analysis revealed complex chromosomal rearrangements including marker chromosomes. CONCLUSIONS: A99 is the first cell line reported to be derived from a primary SCC of the pancreas. The establishment of this cell line may serve as a useful model system for studying the cell biology of this rare cancer or for evaluating novel targeted agents in preclinical models.
Authors: Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch Journal: Ann Surg Date: 2002-01 Impact factor: 12.969
Authors: S A Hahn; A B Seymour; A T Hoque; M Schutte; L T da Costa; M S Redston; C Caldas; C L Weinstein; A Fischer; C J Yeo Journal: Cancer Res Date: 1995-10-15 Impact factor: 12.701
Authors: Anil V Parwani; Joseph Geradts; Eric Caspers; G Johan Offerhaus; Charles J Yeo; John L Cameron; David S Klimstra; Anirban Maitra; Ralph H Hruban; Pedram Argani Journal: Mod Pathol Date: 2003-04 Impact factor: 7.842
Authors: Ralph Meuwissen; Sabine C Linn; R Ilona Linnoila; John Zevenhoven; Wolter J Mooi; Anton Berns Journal: Cancer Cell Date: 2003-09 Impact factor: 31.743
Authors: Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue Journal: Am J Surg Pathol Date: 2012-02 Impact factor: 6.394
Authors: Ya'an Kang; Ran Zhang; Rei Suzuki; Shao-qiang Li; David Roife; Mark J Truty; Deyali Chatterjee; Ryan M Thomas; James Cardwell; Yu Wang; Huamin Wang; Matthew H Katz; Jason B Fleming Journal: Lab Invest Date: 2014-12-08 Impact factor: 5.662